NCT01617538

Brief Summary

Objective: To monitor and evaluate the change of intracranial hemodynamics and MCA stenosis after 24-week atorvastatin treatment using CEUS, CTA and DSA. Study design: Total 30 patients (60 arteries) will be enrolled in this study, who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke. Eligible patient will receive atorvastatin 40mg treatment for 24 weeks. Hemodynamics changes and MCA stenosis will be evaluated using CEUS at baseline, 3-month,and 6-month. MCA stenosis, bloodstream velocity, as well as clinical symptoms will be assessed at each visit and compared to baseline.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2012

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 4, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 12, 2012

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

June 12, 2012

Status Verified

June 1, 2012

Enrollment Period

1.2 years

First QC Date

June 4, 2012

Last Update Submit

June 11, 2012

Conditions

Keywords

atherosclerosisstenosisstatin therapySigns and SymptomsCirculatory; Change

Outcome Measures

Primary Outcomes (1)

  • Hemodynamics changes and MCA stenosis

    Hemodynamics changes will be evaluaed using CEUS at baseline, 3-month,and 6-month.in order to evaluate the effect of atorvastatin, we will compare the baseline with 3-month,and compare the baseline with 6-month.a statistic analysis of measure data is conducted by the group T test,which conducted by SAS 9.13 English edition .

    given atorvastatin 40mg treatment for 24 weeks

Study Arms (2)

Atorvastatin

EXPERIMENTAL

30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.

Drug: atorvastatin

compare

NO INTERVENTION

30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.

Interventions

40mg per day,duration for 24 weeks

Also known as: brand names :FIZER
Atorvastatin

Eligibility Criteria

Age40 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who had MCA infarction of unilateral with moderate to severe stenosis within 6 months prior to screening, and has not received any statins treatment before stroke.

You may not qualify if:

  • With side of extracranial carotid artery 70-100% severe narrow or block
  • Vertebrobasilar artery lesions caused by cerebral infarction
  • Have rheumatic heart disease, the atrial fibrillation of heart disease, those who Cerebral hemorrhage patients
  • Serious liver and kidney function is not complete patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

FuXing Hospital,Capital Medicial University

Beijing, 100038, China

RECRUITING

MeSH Terms

Conditions

Constriction, PathologicAtherosclerosisSigns and Symptoms

Interventions

Atorvastatin

Condition Hierarchy (Ancestors)

Pathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipids

Study Officials

  • Zhong Qin, master

    science study Dept

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Xu Bin

Study Record Dates

First Submitted

June 4, 2012

First Posted

June 12, 2012

Study Start

January 1, 2012

Primary Completion

March 1, 2013

Study Completion

September 1, 2013

Last Updated

June 12, 2012

Record last verified: 2012-06

Locations